Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Effect of Finerenone on Chronic Kidney Disease Outcomes in Type 2 Diabetes

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Breast Cancer Risk Genes - Association Analysis in More than 113,000 Women

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Cardiac Myosin Activation with Omecamtiv Mecarbil in Systolic Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Remdesivir for the Treatment of Covid-19 - Final Report

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • George L Bakris
  • Rajiv Agarwal
  • Stefan D Anker
  • Bertram Pitt
  • Luis M Ruilope
  • Peter Rossing
  • Peter Kolkhof
  • Christina Nowack
  • Patrick Schloemer
  • Amer Joseph
  • Gerasimos Filippatos
  • FIDELIO-DKD Investigators
Vis graf over relationer

BACKGROUND: Finerenone, a nonsteroidal, selective mineralocorticoid receptor antagonist, reduced albuminuria in short-term trials involving patients with chronic kidney disease (CKD) and type 2 diabetes. However, its long-term effects on kidney and cardiovascular outcomes are unknown.

METHODS: In this double-blind trial, we randomly assigned 5734 patients with CKD and type 2 diabetes in a 1:1 ratio to receive finerenone or placebo. Eligible patients had a urinary albumin-to-creatinine ratio (with albumin measured in milligrams and creatinine measured in grams) of 30 to less than 300, an estimated glomerular filtration rate (eGFR) of 25 to less than 60 ml per minute per 1.73 m2 of body-surface area, and diabetic retinopathy, or they had a urinary albumin-to-creatinine ratio of 300 to 5000 and an eGFR of 25 to less than 75 ml per minute per 1.73 m2. All the patients were treated with renin-angiotensin system blockade that had been adjusted before randomization to the maximum dose on the manufacturer's label that did not cause unacceptable side effects. The primary composite outcome, assessed in a time-to-event analysis, was kidney failure, a sustained decrease of at least 40% in the eGFR from baseline, or death from renal causes. The key secondary composite outcome, also assessed in a time-to-event analysis, was death from cardiovascular causes, nonfatal myocardial infarction, nonfatal stroke, or hospitalization for heart failure.

RESULTS: During a median follow-up of 2.6 years, a primary outcome event occurred in 504 of 2833 patients (17.8%) in the finerenone group and 600 of 2841 patients (21.1%) in the placebo group (hazard ratio, 0.82; 95% confidence interval [CI], 0.73 to 0.93; P = 0.001). A key secondary outcome event occurred in 367 patients (13.0%) and 420 patients (14.8%) in the respective groups (hazard ratio, 0.86; 95% CI, 0.75 to 0.99; P = 0.03). Overall, the frequency of adverse events was similar in the two groups. The incidence of hyperkalemia-related discontinuation of the trial regimen was higher with finerenone than with placebo (2.3% and 0.9%, respectively).

CONCLUSIONS: In patients with CKD and type 2 diabetes, treatment with finerenone resulted in lower risks of CKD progression and cardiovascular events than placebo. (Funded by Bayer; FIDELIO-DKD ClinicalTrials.gov number, NCT02540993.).

OriginalsprogEngelsk
TidsskriftThe New England journal of medicine
Vol/bind383
Udgave nummer23
Sider (fra-til)2219-2229
Antal sider11
ISSN0028-4793
DOI
StatusUdgivet - 3 dec. 2020

Bibliografisk note

Copyright © 2020 Massachusetts Medical Society.

ID: 61375637